- IMU-838, a DHODH Inhibitor taken in tablet form
- Demonstrated antiviral activity against SARS-CoV-2
- Attractive pharmacokinetic, safety and tolerability profile and, to date, has already been tested in about 650 individuals.
- Clinical trials for COVID-19 scheduled to start this month
“The broad antiviral activity of IMU-838 has been well documented and preclinical testing affirms the antiviral activity of IMU-838 against SARS-CoV-2.
As a result, we are exploring the initiation of a phase 2 clinical trial to determine if IMU-838 could be a meaningful therapeutic option for the current worldwide pandemic caused by COVID-19 and potential future pandemic threats,”Daniel Vitt, Ph.D. – CEO, Immunic